Extended Data Fig. 3: AGO2 is regulated by the Pi3K-AKT-mTOR pathway at least in part through levels of TNRC6.
From: AGO2 silences mobile transposons in the nucleus of quiescent cells
(a) Chemical inhibition of Pi3K-AKT-mTOR and MEK-ERK pathways in immortalized MEFs. A schematic representation of the Pi3K pathway and the drugs used for its inhibition is shown on the left (Pi3Ki, LY294002; AKTi, MK2206; mTORi, Torin1). (b) Top, schematic representation of the MEK-ERK mitogenic pathway and the drug used to inhibit is (MEKi, PD032590). Bottom, western blot showing activity of the pathway in resting (Res) and activated (Act) splenocytes. (c) Western blot showing AGO2 and TNRC6 levels in primary MEFs cultured in complete media (Fed), serum starved (Str), or starved and refeed for 24 h (Ref). (d) TNRC6 levels but not AGO2 levels are downregulated by Pi3K pathway inhibitors. (e) qPCR to Tnrc6 family members following the delivery of indicated siRNAs to immortalized MEFs. Data are presented as mean values of three independent experiments +/− SD. p-values were calculated using a two-sided Wilcoxon test. (f) Western blot to TNRC6 following downregulation of all three isoforms.
